248 related articles for article (PubMed ID: 29967183)
1. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.
Hosoya T; Sato-Kaneko F; Ahmadi A; Yao S; Lao F; Kitaura K; Matsutani T; Carson DA; Hayashi T
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6836-E6844. PubMed ID: 29967183
[TBL] [Abstract][Full Text] [Related]
2. Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand.
Wu CC; Crain B; Yao S; Sabet M; Lao FS; Tawatao RI; Chan M; Smee DF; Julander JG; Cottam HB; Guiney DG; Corr M; Carson DA; Hayashi T
J Innate Immun; 2014; 6(3):315-24. PubMed ID: 24192551
[TBL] [Abstract][Full Text] [Related]
3. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.
Adlard AL; Dovedi SJ; Telfer BA; Koga-Yamakawa E; Pollard C; Honeychurch J; Illidge TM; Murata M; Robinson DT; Jewsbury PJ; Wilkinson RW; Stratford IJ
Int J Cancer; 2014 Aug; 135(4):820-9. PubMed ID: 24390981
[TBL] [Abstract][Full Text] [Related]
4. Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.
Hayashi T; Chan M; Norton JT; Wu CC; Yao S; Cottam HB; Tawatao RI; Corr M; Carson DA; Daniels GA
Melanoma Res; 2011 Feb; 21(1):66-75. PubMed ID: 21030882
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
6. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
[TBL] [Abstract][Full Text] [Related]
7. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
8. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.
Koga-Yamakawa E; Dovedi SJ; Murata M; Matsui H; Leishman AJ; Bell J; Ferguson D; Heaton SP; Oki T; Tomizawa H; Bahl A; Takaku H; Wilkinson RW; Harada H
Int J Cancer; 2013 Feb; 132(3):580-90. PubMed ID: 22733292
[TBL] [Abstract][Full Text] [Related]
9. CD4
Doorduijn EM; Sluijter M; Salvatori DC; Silvestri S; Maas S; Arens R; Ossendorp F; van der Burg SH; van Hall T
Cancer Immunol Res; 2017 Aug; 5(8):642-653. PubMed ID: 28637878
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
11. A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma.
Lin G; Wang X; Yi W; Zhang C; Xu G; Zhu X; Cai Z; Liu Y; Diao Y; Lin MC; Jin G
J Transl Med; 2015 May; 13():166. PubMed ID: 25990580
[TBL] [Abstract][Full Text] [Related]
12. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation.
Diao Y; Wang X; Wan Y; Zhong J; Gao D; Liu Y; Gao N; Li W; Liu B; Huang X; Jin Z; Peng B; Wang Z; Fu L; Chen S; Jin G
Oncol Rep; 2016 Feb; 35(2):793-800. PubMed ID: 26718332
[TBL] [Abstract][Full Text] [Related]
14. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
15. TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice.
Koga-Yamakawa E; Murata M; Dovedi SJ; Wilkinson RW; Ota Y; Umehara H; Sugaru E; Hirose Y; Harada H; Jewsbury PJ; Yamamoto S; Robinson DT; Li CJ
Cancer Immunol Immunother; 2015 Oct; 64(10):1229-39. PubMed ID: 26091797
[TBL] [Abstract][Full Text] [Related]
16. Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model.
Narayanan JSS; Ray P; Hayashi T; Whisenant TC; Vicente D; Carson DA; Miller AM; Schoenberger SP; White RR
Cancer Immunol Res; 2019 Oct; 7(10):1714-1726. PubMed ID: 31409607
[TBL] [Abstract][Full Text] [Related]
17. Innate and adoptive immune cells contribute to natural resistance to systemic metastasis of B16 melanoma.
Umeshappa CS; Zhu Y; Bhanumathy KK; Omabe M; Chibbar R; Xiang J
Cancer Biother Radiopharm; 2015 Mar; 30(2):72-8. PubMed ID: 25714591
[TBL] [Abstract][Full Text] [Related]
18. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
20. A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation.
Wang X; Yu B; Cao B; Zhou J; Deng Y; Wang Z; Jin G
Int J Cancer; 2021 Jan; 148(2):437-447. PubMed ID: 32683685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
